What is astagraf?

See the DrugPatentWatch profile for astagraf

What is Astagraf, and how does it compare to other immunosuppressants?

Astagraf is an immunosuppressant medication, specifically a calcineurin inhibitor, used to prevent the rejection of organ transplants in patients. Developed by Astellas Pharma, it is a branded version of the generic medication tacrolimus.

How long does Astagraf's patent last?

The Astagraf patent, which was first granted in 2003, expires in 2025, although the generic tacrolimus has been available since 1998 [1]. This means that generic versions of Astagraf may enter the market soon.

Difference between Astagraf and tacrolimus:

The main difference between Astagraf and generic tacrolimus is the manufacturing process and the proprietary packaging of Astagraf. Astagraf's proprietary packaging aims to improve patient compliance by providing a prefilled syringe that simplifies the dosing process.

How does Astagraf compare to other immunosuppressants?

Astagraf is often used in combination with other medications, such as mycophenolate mofetil, and corticosteroids, to prevent transplant rejection. It is generally considered a preferred option due to its efficacy and lower risk of side effects compared to other immunosuppressants [2].

Side effects and safety concerns:

Common side effects of Astagraf include hypertension, diarrhea, tremors, and elevated liver enzymes. Patients should closely monitor their blood pressure and kidney function while taking Astagraf [3].

Who makes Astagraf, and where can I find more information?

Astagraf is manufactured and distributed by Astellas Pharma. For more information about Astagraf, including its prescribing information, patient education, and clinical trials, visit Astellas Pharma's website or consult reputable resources like the FDA or DrugPatentWatch.com [4].

Sources:

[1] DrugPatentWatch.com (2023). Astagraf (Astellas Pharma).

[2] Astellas Pharma (2022). Astagraf XL (Prescribing Information).

[3] ClinicalTrials.gov (2023). Astagraf clinical trials.

[4] Astellas Pharma (2023). Astagraf (Product Information).

Note: This response is intended to provide general information and not to be considered medical advice. Consult a healthcare professional for personalized guidance on treating transplant rejection patients with Astagraf.